Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.

SG&A Expenses: A Tale of Two Companies

In the world of biotechnology, operational efficiency is key. Amgen Inc., a giant in the industry, and Soleno Therapeutics, Inc., a smaller player, offer a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Amgen's SG&A expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, a 31% rise from 2014. In contrast, Soleno's expenses, though significantly smaller, have also grown, reaching around $13.5 million in 2023, marking a 362% increase from 2014. This stark difference highlights the scale and growth dynamics between established and emerging biotech firms. While Amgen's expenses reflect its expansive operations, Soleno's growth in SG&A spending underscores its strategic investments in scaling operations. This comparison offers valuable insights into how companies of different sizes manage their operational costs in a competitive industry.